June 13, 2013 ·
Leave a comment
June 13, 2013 (CHAPEL HILL, NC) Thought Leader Select, a Chapel Hill, NC-based consulting firm serving the biopharmaceutical, medical device, and diagnostics industries, announces the commencement of a medical strategy engagement in gastroenterology with a leading U.S. biopharmaceutical company.
The company, a global leader in drug development for products aiding patients in recovery from a variety of gastrointestinal surgeries, approached Thought Leader Select for support with planned initiatives with key opinion leaders and centers of excellence in the field.
Thought Leader Select is identifying and profiling thought leaders in colorectal and general surgery across the United States. The in-house research group at Thought Leader Select is applying its objective, validated methodology to assess the skills and experiences, as well as the clinical and research interests, of KOLs specializing in surgery of the colon, rectum, and bowels.
Known for the versatility of applications for its in-house research, Thought Leader Select’s advisory team will also plan engagement strategies to optimize the talents and contributions that the key opinion leaders will bring to several initiatives for the client company, including late-stage clinical trial work, as well as publication and speaking opportunities. The KOLs will also work on issues within appropriate regulatory bodies, as well as patient advocacy and awareness, and treatment guidelines involvement.
In addition to its work with key opinion leaders, Thought Leader Select’s research group ... read more »
TAGS: 
advisory boards basic research biopharmaceutical biotechnology centers of excellence clinical research clinical trials gastroenterological surgery gastroenterology experts gastroenterology KOLs health care professionals health care providers key opinion leaders KOL KOL engagement KOL identification KOL mapping KOL profiling KOLs medical experts Neil Mellor pharma pharmaceutical physicians therapeutic areas Thought Leader Select thought leaders
May 29, 2013 ·
Leave a comment
We were inspired by a recent PharmaLive story on Lilly’s new initiative highlighting the key work that medical professionals undertake at the company during all facets and phases of drug discovery and development.
The story notes that over 500 physicians, 700 pharmacists, and 1400 medical research scientists work at Lilly, and the company is touting their work with the medical community to bring new treatments to market, all while keeping patient needs first.
While many are either skeptical or unaware of these interactions, the article speaks to why we are in the business of what we do at Thought Leader Select—delivering key information to pharmaceutical, biotechnology, and medical device companies so that external relations officials at companies like Lilly can optimize their medical community interactions in the service of patients.
Companies in life science disciplines utilize key opinion leaders in medicine in a host of ways to ensure that new treatments target unmet medical needs and have the best impact possible on patient outcomes. Their collaborative work results in clinical research, patient advocacy, bioethics, regulatory compliance, and medical education, all key drivers in medicine today.
Thought Leader Select is proud that our work in identifying and profiling the right key opinion leaders and medical centers of excellence to collaborate with industry in these many contexts and more optimizes these industry/medical community relationships for ... read more »
TAGS: biopharmaceutical biotechnology Eli Lilly ethics and transparency health outcomes industry-based medical professionals key opinion leaders in medicine KOL engagement KOLs Lilly medical device medical research scientists medical treatments patient care Patients Matter Most pharmaceuticals pharmacists PharmaLive physicians Thought Leader Select
February 26, 2013 ·
Leave a comment
For Immediate Release
February 21, 2013 (CHAPEL HILL, NC) Thought Leader Select, a North Carolina-based key opinion leader strategy company, announces the hiring of Heather Langan as research director.
In her new role at the company, Langan will lead profiling and engagement planning related to the skills and experience of both leading physicians and other health care professionals, as well as medical centers of excellence that advance the medical science. Life sciences companies use this research and advice for better strategic decision-making for collaborations with medical experts, as industry works with these experts to bring new treatments to market for better patient care and better public health outcomes.
Langan arrives at Thought Leader Select after a decorated career in human services, working and leading teams in developmental disabilities, family therapy, and mental health. In her most recent role at Duke University’s National Center for Child Traumatic Stress, Langan led quality assurance and continuous improvement at the premier center of excellence in the area of child trauma, influencing the treatment decisions in evidence-based clinics around the country.
Heather Langan holds two bachelor’s degrees, in philosophy and psychology, from the University of Utah. After graduation, Langan also earned a pair of master’s degrees in psychology and counseling, from Stephen F. Austin University and North ... read more »
TAGS: biopharmaceutical centers of excellence developmental disabilities Duke University family therapy health care professionals Heather Langan Human Services key opinion leaders KOL engagement KOL engagement planning KOL identification KOL profiling leading physicians medical research medicine mental health National Center for Child Traumatic Stress patient care Paul Meade public health outcomes Thought Leader Select
December 20, 2012 ·
Leave a comment
December 20, 2012 (CHAPEL HILL, NC) Thought Leader Select, a Chapel Hill, NC-based consulting firm serving the biopharmaceutical, medical device, and diagnostics industries, announces the commencement of a medical strategy engagement in pulmonology with a top Canadian biopharmaceutical company.
The company, part of a select group of global leaders in drug development for products treating chronic obstructive pulmonary disorder (COPD), approached Thought Leader Select for support with scientific advisory boards and continuing health education (CHE) initiatives across multiple Canadian provinces. Having already worked with Thought Leader Select to form rosters of key opinion leaders in Canadian rheumatology and oncology circles, the company will formulate its panel of key experts in pulmonology by deploying Thought Leader Select’s team to assess the skills and experiences of physician specialists across the country.
Known for the versatility of applications for its in-house research, Thought Leader Select’s research group will analyze the skills and experience of these leading experts in multiple areas where they collaborate to advance the science of medicine and patient care, including basic and clinical research, scientific journal publishing, treatment guidelines, and more.
Throughout the remainder of the engagement, Thought Leader Select’s consulting team will provide strategic guidance, tactical recommendations for strengthening key opinion leader relationships in the nursing and pharmacy communities, and a suite of tools to promote collaborative work with KOLs. Among these ... read more »
TAGS: advisory boards basic research biopharmaceutical biotechnology chronic obstructive pulmonary disorder clinical trials COPD deep-profiling health care professionals health care providers healthcare key opinion leaders KOL KOL deployment KOL engagement KOL identification KOL mapping KOL profiling KOLs medical devices Neil Mellor oncology KOLs pharmaceutical pharmaceuticals physicians pulmonology rheumatology KOLs Thought Leader Select thought leaders treatment guidelines
October 4, 2012 ·
Leave a comment
(CHAPEL HILL, NC) Thought Leader Select, a Chapel Hill, NC-based consulting firm serving the biopharmaceutical, medical device, and diagnostics industries, announces the commencement of a national engagement in obesity with a top U. S. biopharmaceutical company.
The company, part of a select group of global leaders in drug development for products treating the condition of obesity, approached Thought Leader Select for support with scientific advisory boards, consulting, and medical science liaison outreach to leading physicians in this area. Having already worked with Thought Leader Select to form rosters of key opinion leaders in endocrinology, primary care, nursing, pharmacy, and long-term care in the treatment of type I and type II diabetes, the company has now chosen Thought Leader Select to pinpoint the leading experts in the treatment of obesity in the United States.
Known for the versatility of applications for its in-house research, Thought Leader Select’s research group will analyze the skills and experience of specialists in multiple areas where they collaborate with leading physicians to advance the science of medicine and patient care, including basic and clinical research, scientific journal publishing, treatment guidelines, and more.
Throughout the remainder of the engagement, Thought Leader Select’s consulting team will provide strategic guidance, tactical recommendations for strengthening key opinion leader relationships in the area of obesity, and a suite of tools to promote collaborative work ... read more »
TAGS: advisory boards biopharmaceutical biotechnology Brian Castle clinical research drug development health care professionals health care providers healthcare key opinion leader key opinion leaders KOL KOL engagement KOL identification KOL mapping KOL profiling KOLs medical experts medicine obesity obesity key opinion leaders obesity specialists public health
September 27, 2012 ·
Leave a comment
(CHAPEL HILL, NC) Thought Leader Select, a Chapel Hill, NC-based consulting firm serving the biopharmaceutical, medical device, and diagnostics industries, announces the commencement of a national engagement in gastroenterology with a top Canadian biopharmaceutical company.
The company, part of a select group of global leaders in drug development for products treating type and type II diabetes, approached Thought Leader Select for support with scientific advisory boards and continuing health education (CHE) initiatives across multiple Canadian provinces. Having already worked with Thought Leader Select to form a roster of key opinion leaders in Canadian endocrinology circles, the company will round out its roster of key opinion leaders by deploying Thought Leader Select’s team to assess the skills and experiences of registered nurses and clinical pharmacists around the country.
Known for the versatility of applications for its in-house research, Thought Leader Select’s research group will analyze the skills and experience of registered nurses and pharmacists in multiple areas where they collaborate with leading physicians to advance the science of medicine and patient care, including basic and clinical research, scientific journal publishing, treatment guidelines, and more.
Throughout the remainder of the engagement, Thought Leader Select’s consulting team will provide strategic guidance, tactical recommendations for strengthening key opinion leader relationships in the nursing and pharmacy communities, and a suite of tools to promote collaborative work with KOLs.
“Thought ... read more »
TAGS: advisory boards basic research biopharmaceutical biotechnology clinical pharmacists clinical research clinical trials deep-profiling diabetes health care professionals health care providers key opinion leader key opinion leaders KOL KOL engagement KOL identification KOL mapping KOL profiling medical experts Neil Mellor pharmaceuticals registered nurses Thought Leader Select type 1 diabetes type 2 diabetes
June 21, 2012 ·
Leave a comment
June 21, 2012 (CHAPEL HILL, NC) Thought Leader Select, a Chapel Hill, NC-based consulting firm serving the biopharmaceutical, medical device, and diagnostics industries, announces the commencement of a national engagement in gastroenterology with a top 10 global biopharmaceutical company.
The company, part of a select group of global leaders in drug development for products treating exocrine pancreatic insufficiency (EPI), approached Thought Leader Select for support with scientific advisory boards in support of a new product initiative. To meet the strategic needs of the company’s advisory board activities in support of the new treatment, Thought Leader Select will deploy its in-house research group for an assessment of community-based key opinion leaders in gastroenterology throughout the United States.
Known for the versatility of applications for its in-house research, Thought Leader Select’s research group will analyze the skills and experience of leading specialists in multiple areas where they advance the science of medicine and patient care, including basic and clinical research, scientific journal publishing, treatment guidelines, and more.
For the national assessment, the Thought Leader Select research group will collaborate with a team of national key opinion leaders in gastroenterology to identify community-based physicians for grassroots-level scientific advisory work. Thought Leader Select will combine the key opinion leader recommendations with the experience data to optimize a pool of leading physicians with broad representation across multiple geographic ... read more »
TAGS: advisory boards biopharmaceutical clinical research community-based gastroenterologists EPI exocrine pancreatic insufficiency gastroenterology health care professionals health care providers healthcare key opinion leaders KOL KOL deployment KOL engagement KOL identification KOL mapping KOL profiling KOLs medical experts pharmaceutical physicians therapeutic areas Thought Leader Select
June 14, 2012 ·
Leave a comment
June 14, 2012 (CHAPEL HILL, NC) Thought Leader Select, a Chapel Hill, NC-based consulting firm serving the biopharmaceutical, medical device, and diagnostics industries, announces the commencement of a global engagement in blood disorders with a top 30 global biopharmaceutical company.
The biopharmaceutical company, part of a select group of global leaders in drug development for a product in development to treat iron overload in the body, approached Thought Leader Select for support with its launch activities across multiple global markets. To meet the strategic needs of the company’s pre-launch for a new blood disorders treatment, Thought Leader Select will deploy its in-house research group for an assessment of key opinion leaders in the area of chelation therapy.
Known for the versatility of applications for its in-house research, Thought Leader Select’s research group will analyze the skills and experience of leading specialists in the following geographic areas:
- United States
- Europe
- Japan
- Pacific Rim
- Middle East
For the global assessment, the Thought Leader Select research group will identify 100 physicians appropriate for compliant engagement in support of drug development for blood disorders.
In the second phase of the assessment, Thought Leader Select’s in-house research group will engage in its exclusive, validated methodology of deep profiling, delivering objective assessments of the skills and experience of key opinion leaders across 14 areas where health care professionals define themselves as thought ... read more »
TAGS: advisory boards basic research biopharmaceutical biotechnology blood disorders chelation therapy clinical research clinical trials drug development drug launch iron overload key opinion leader relationships key opinion leaders KOL KOL engagement KOL identification KOL profiling KOL reserch Kristen Smithwick medical congresses medical experts Neil Mellor pharmaceutical physicians scientific journal publishing Thought Leader Select treatment guidelines
April 18, 2012 ·
Leave a comment
April 18, 2012 (CHAPEL HILL, NC) Thought Leader Select, a Chapel Hill, NC-based consulting firm serving the biopharmaceutical, medical device, and diagnostics industries, announces the commencement of a urology engagement with a top 20 global pharmaceutical company.
The pharmaceutical company, a global leader in drug development for urological conditions, approached Thought Leader Select for support with its existing portfolio of medicines, as well as new drugs in its development pipeline across the Canadian market. To meet the combined strategic needs of the company’s existing portfolio as well as its emerging pipeline, Thought Leader Select will deploy its in-house research group for a two-part assessment of the key opinion leader community in urology.
For the first wave of the assessment, the Thought Leader Select research group will validate the skills and experience of the urology specialists that currently comprise the company’s KOL roster. In addition, Thought Leader Select will identify new physicians appropriate for the panel, bringing the total roster to 40 thought leaders across multiple Canadian provinces.
In the second phase of the assessment, Thought Leader Select’s in-house research group will engage in its exclusive, validated methodology of deep profiling, delivering objective assessments of the skills and experience of key opinion leaders across 14 areas where health care professionals define themselves as ... read more »
TAGS: basic and clinical research biopharmaceutical diagnostics drug development key opinion leaders KOL engagement KOL identification KOL panel KOL profiling KOL roster KOLs in urology Kristen Smithwick medical devices medical meetings pharmaceuticals scientific journal publishing Thought Leader Select thought leaders treatment guidelines urology
March 27, 2012 ·
Leave a comment
Industry Insights from Kristen Smithwick
Albeit a bit late, the U. S. Centers for Medicare and Medicaid Services (CMS) issued a proposed rule on the Patient Protection & Affordable Care Act’s Physician Payments Sunshine Provision (also known as the “Sunshine Act”) to implement it as law.
CMS invited comments on the proposed rule through mid-February 2012, and a recent webcast, sponsored by PharmaLive’s Pharmalot, featured key facts and summaries of comments on the proposed rule. Working for a provider of research and consulting to the biopharmaceutical, medical device, and diagnostics industries on relationships with physicians and other health care providers, I enjoyed the opportunity to join the webcast, led by experts from Buchanan Ingersoll & Rooney, P.C., and am eager to share some of my key takeaways.
As mentioned in previous Thought Leader Select Blog posts, the Sunshine Act, as with many laws and regulations, is full of unintended consequences – some positive and some negative. Lance K. Stell, medical ethics teacher at Davidson College and Carolinas Medical Center, reports in his USA Today op-ed piece that the “Sunshine Act will cost far more than the $224 million estimated for just the first year of compliance” and that “the biggest cost will be the valuable, socially useful physician-industry collaborations that simply won’t occur.” Of course, the idea of ... read more »
TAGS: AdvaMed BIO biopharmaceutical biotechnology Buchanan Ignersoll & Rooney CMS Davidson College Carolinas Medical Center diagnostics HCP payments health care providers Kristen Smithwick Lance Stell medical device medical ethics OTC manufacturer Patient Protection and Affordable Care Act pharmaceutical PharmaLive Pharmalot PhRMA Physician Payments Sunshine Provision physicians Sunshine Act Thought Leader Select Thought Leader Select Blog US Centers for Medicare and Medicaid Services veterinarians veterinary schools
Older posts »
